- Home
- RLX vs KOD Comparison
RLX vs KOD Comparison
Compare RLX & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | KOD |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RLX | KOD |
|---|---|---|
| Price | $1.69 | $32.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.50 | ★ $35.43 |
| AVG Volume (30 Days) | ★ 3.0M | 670.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.89 | N/A |
| Revenue Next Year | $15.07 | N/A |
| P/E Ratio | $28.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $10.94 |
| 52 Week High | $2.68 | $47.84 |
Technical Indicators
Market Signals| Indicator | RLX | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 41.02 |
| Support Level | $1.67 | $32.93 |
| Resistance Level | $2.08 | $45.77 |
| Average True Range (ATR) | 0.04 | 1.84 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 25.00 | 56.58 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.